# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ionis intends to use the net proceeds from the offering to fund its independent commercial launches, late-stage clinical progra...
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and raises the price target from ...
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target...
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Sell and raises the price target ...
Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight and raises the price target fro...